PHOENIX DDR-Anti-PD-L1 Trial

PHOENIX DDR/Anti-PD-L1 Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemotherapy resistant residual triple negative breast cancer

Existing samples:

  • Malignant tumor of breast (disorder)

Contact Information

Email:
phoenix-icrctsu@icr.ac.uk
Address:

Clinical Trials and Statistics Unit (ICR-CTSU)
The Institute of Cancer Research
15 Cotswold Road
Belmont
 Sutton
Surrey
SM2 5NG
England

Last Updated: 08/17/2018


Annual Statistics

Year Access Requests Received Access Requests Approved
Internal External Commercial Internal External Commercial
2015 N/A N/A N/A N/A N/A N/A
2016 N/A N/A N/A N/A N/A N/A
2017 N/A N/A N/A N/A N/A N/A
2018 N/A N/A N/A N/A N/A N/A
2019 N/A N/A N/A N/A N/A N/A
2020 N/A N/A N/A N/A N/A N/A
2021 N/A N/A N/A N/A N/A N/A
2022 N/A N/A N/A N/A N/A N/A
2023 N/A N/A N/A N/A N/A N/A
2024 N/A N/A N/A N/A N/A N/A